Form 4: Esperion Therapeutics Executive Eric Warren Reports Sale of Shares for Tax Obligations
SEC Form 4 Filing
Esperion Therapeutics' Chief Commercial Officer, Eric Warren, reports the sale of 2,608 shares of common stock to cover tax obligations arising from vested restricted stock units.
Summary
- On September 17, 2024, Eric Warren, Chief Commercial Officer of Esperion Therapeutics, Inc., sold 2,608 shares of common stock.
- The shares were sold at a price of $1.783 per share.
- The transaction was executed to satisfy tax obligations related to vested restricted stock units.
- Following the transaction, Warren directly owns 162,659 shares of Esperion Therapeutics.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding a stock sale for tax purposes, which is neither particularly positive nor negative.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to the market.
Stakeholder Impact
- The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.
Key Dates
| Date | Description |
|---|---|
| February 28, 2022 | Date of execution of the Limited Power of Attorney. |
| September 17, 2024 | Date of the transaction (sale of shares). |
| September 18, 2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.